CBWTF:OTC-Auxly Cannabis Group Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.23

Change

0.00 (0.00)%

Market Cap

USD 0.19B

Volume

0.78M

Average Target Price

USD 0.60 (+161.44%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Auxly Cannabis Group Inc., a cannabis company, provides cannabis products to the medical, wellness, and adult-use markets in Canada. The company engages in the cultivation, development, and distribution of cannabis products. It offers products such as, soft chews, vape cartridges, vape pens, pre-rolled cannabis, chocolates, cannabis oil spray, and oil drops through retail stores under the Kolab Project, Foray, and Dosecan brand names. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is based in Vancouver, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD80.36B 29.16 17.26
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD79.39B 28.51 17.26
TKPHF Takeda Pharmaceutical Company ..

N/A

USD54.07B 15.78 0.07
ESALY Eisai Co., Ltd

N/A

USD31.03B 81.65 0.19
ESALF Eisai Co., Ltd

N/A

USD29.49B 76.17 0.19
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD23.06B 29.29 4.17
SGIOY Shionogi & Co., Ltd

N/A

USD15.39B 15.49 0.07
SGIOF Shionogi & Co., Ltd

N/A

USD15.14B 15.25 0.07
TEVJF Teva Pharmaceutical Industries..

N/A

USD11.26B 900.00 16.02
BAYP Bayport International Holdings..

N/A

USD10.85B N/A N/A

ETFs Containing CBWTF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.09% 46% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.09% 46% F 48% F
Trailing 12 Months  
Capital Gain -4.77% 34% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.77% 34% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -26.77% 15% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.77% 15% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 29.62% 92% A- 66% D
Risk Adjusted Return -90.37% 7% F 2% F
Market Capitalization 0.19B 81% B- 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.12 69% D+ 65% D
Price / Cash Flow Ratio -5.84 63% D 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -37.62% 50% F 21% F
Return on Invested Capital -13.91% 50% F 23% F
Return on Assets -6.90% 63% D 35% F
Debt to Equity Ratio 56.41% 17% F 32% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 2.23 20% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector